68 related articles for article (PubMed ID: 15505609)
1. Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes.
Pantin J; Tian X; Shah AA; Kurlander R; Ramos C; Cook L; Khuu H; Stroncek D; Leitman S; Barrett J; Donohue T; Young NS; Geller N; Childs RW
Am J Hematol; 2013 Oct; 88(10):874-82. PubMed ID: 23813900
[TBL] [Abstract][Full Text] [Related]
2. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency.
Grossman J; Cuellar-Rodriguez J; Gea-Banacloche J; Zerbe C; Calvo K; Hughes T; Hakim F; Cole K; Parta M; Freeman A; Holland SM; Hickstein DD
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1940-8. PubMed ID: 25111582
[TBL] [Abstract][Full Text] [Related]
3. Favorable outcomes in patients with high donor-derived T cell count after in vivo T cell-depleted reduced-intensity allogeneic stem cell transplantation.
Toor AA; Sabo RT; Chung HM; Roberts C; Manjili RH; Song S; Williams DC; Edmiston W; Gatesman ML; Edwards RW; Ferreira-Gonzalez A; Clark WB; Neale MC; McCarty JM; Manjili MH
Biol Blood Marrow Transplant; 2012 May; 18(5):794-804. PubMed ID: 22005648
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation.
Giaccone L; McCune JS; Maris MB; Gooley TA; Sandmaier BM; Slattery JT; Cole S; Nash RA; Storb RF; Georges GE
Blood; 2005 Dec; 106(13):4381-8. PubMed ID: 16144801
[TBL] [Abstract][Full Text] [Related]
5. Abatacept for graft versus host disease prophylaxis in patients 60 years and older receiving mismatched unrelated donor transplantation for hematologic malignancies.
Raghunandan S; Qayed M; Watkins BK; Graiser M; Gorfinkel L; Westbrook A; Gillespie S; Bratrude B; Petrovic A; Suessmuth Y; Horan J; Kean LS; Langston AA
Bone Marrow Transplant; 2023 Nov; 58(11):1264-1266. PubMed ID: 37580397
[No Abstract] [Full Text] [Related]
6. Prolonged chronic graft-versus-host disease is a risk factor for thyroid failure in long-term survivors after matched sibling donor stem cell transplantation for hematologic malignancies.
Savani BN; Koklanaris EK; Le Q; Shenoy A; Goodman S; Barrett AJ
Biol Blood Marrow Transplant; 2009 Mar; 15(3):377-81. PubMed ID: 19203730
[TBL] [Abstract][Full Text] [Related]
7. Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with thymoglobulin GVHD prophylaxis.
Lim AB; Storek J; Beligaswatte A; Collins M; Tacey M; Williamson T; Mason K; Li E; Chaudhry MA; Russell JA; Daly A; Szer J; Lewis I; Ritchie D
Bone Marrow Transplant; 2015 Apr; 50(4):566-72. PubMed ID: 25642763
[TBL] [Abstract][Full Text] [Related]
8. Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors.
Rizzieri DA; Dev P; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Chao NJ
Bone Marrow Transplant; 2009 Feb; 43(4):327-33. PubMed ID: 18850014
[TBL] [Abstract][Full Text] [Related]
9. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.
Brunstein CG; Barker JN; Weisdorf DJ; DeFor TE; Miller JS; Blazar BR; McGlave PB; Wagner JE
Blood; 2007 Oct; 110(8):3064-70. PubMed ID: 17569820
[TBL] [Abstract][Full Text] [Related]
10. Graft versus host disease after stem cell allotransplantation with low-dose total body irradiation, fludarabine, and antithymocyte globulin.
Grosskreutz C; Scigliano E; Osman K; Isola L
Transplantation; 2007 Sep; 84(5):598-604. PubMed ID: 17876272
[TBL] [Abstract][Full Text] [Related]
11. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
12. Unrelated donor hematopoietic stem cell transplantation for patients with hematologic malignancies using a nonmyeloablative conditioning regimen of fludarabine, low-dose total body irradiation, and rabbit antithymocyte globulin.
Rowley SD; Goldberg SL; Pecora AL; Hsu JS; Brecher BA; Butrin L; Kobbe K; McKiernan P; Preti R
Biol Blood Marrow Transplant; 2004 Nov; 10(11):784-93. PubMed ID: 15505609
[TBL] [Abstract][Full Text] [Related]
13. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
15. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
Bornhäuser M; Thiede C; Platzbecker U; Jenke A; Helwig A; Plettig R; Freiberg-Richter J; Röllig C; Geissler G; Lutterbeck K; Oelschlagel U; Ehninger G
Clin Cancer Res; 2001 Aug; 7(8):2254-62. PubMed ID: 11489799
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
